Why the study?
The measurement of biomarkers in pleural fluid plays a crucial role in the diagnosis of malignant pleural effusion.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review summarizes the utility of four classes of biomarkers in diagnosing and characterizing malignant pleural effusions.
The measurement of biomarkers in pleural fluid plays a crucial role in the diagnosis of malignant pleural effusion.Four types of biomarkers are discussed in this review: (1) soluble protein biomarkers, such as combined carcinoembryonic antigen and carbohydrate antigen 15-3, which can provide valuable insights into the malignant nature of an effusion, particularly those with false-negative cytology; (2) immunocytochemical biomarkers, which help establish the mesothelial, epithelial, or other cell origin of a malignant effusion, as well as the primary tumor invading the pleura (e.g., epithelial cell adhesion molecule and claudin-4 in carcinomas, or loss of BRCA1-associated protein 1 and methylthioadenosine phosphorylase in mesotheliomas); (3) flow cytometry biomarkers, which identify lymphoproliferative as well as epithelial neoplasms; and (4) molecular biomarkers (e.g., oncogenic or driver mutations), which phenotypically characterize a tumor and predict its response to target therapy or immunotherapy.
No takes yet. Share an insight, caveat, or question.
Porcel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: